The fight against tamoxifen resistance in breast cancer therapy: A new target in the battle?

Molecular Interventions

Volumn 7, Issue 1, 2007, Pages 13-16

  Nichols, Mark ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; FULVESTRANT; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; HUMAN; NONHUMAN; OSTEOLYSIS; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33847635564     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.7.1.4     Document Type: Review

References (31)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. Cancer statistics, 2007. CA Cancer J Clin. 57, 43-66 (2007.).
2. Gronemeyer, H., Gustafsson, J.Å., and Laudet, V. 2004. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964. (2004). This is a comprehensive review of the nuclear receptor family, how they are involved in metabolic and disease states, and how they can be targeted by selective agonists, antagonists or mixed agonist compounds to gain receptor subtype or tissue specificity.
3. Brzozowski, A.M., Pike, A.C.W., and Dauter, Z. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997). Beautiful first x-ray structure pictures of the ER LBD in its active (estradiol bound) or inactive (raloxifene bound) forms. Helix 12 has two distinct positions.
4. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., and Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998). Another set of x-ray structures that confirm active and inactive positions for Helix 12 in the ER LBD, but this time including a coactivator peptide from GRIP1 with the conserved LxxLL motif. It shows very nicely how Helix 12 occludes coactivator interaction when 4-hydroxytamoxifen is bound.
5. Robyr, D., Wolffe, A.P., and Wahli, W. Nuclear hormone receptor coregulators in action: Diversity for shared tasks. Mol. Endocrinol. 14, 329-347 (2000).
6. Smith, C.L. and O'Malley, B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocrine Rev. 25, 45-71 (2004).
7. Feng, W., Ribeiro, R.C.J., Wagner, R.L., Nguyen, H., Apriletti, J.W., Fletterick, R.J., Baxter, J.D., Kushner, P.J., and West, B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280, 1747-1749 (1998).
8. Shang, Y. and Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002). This paper shows experimentally an elegant description for why tamoxifen, and not raloxifene, is estrogenic in endometrial cells. Expression of SRC-1 is high in endometrial cells, and it can be a coactivator for Tam-ER but not Ral-ER. Tamoxifen and raloxifene are both antagonists in breast cells, where amounts of SRC-1 are low.
9. Fisher, B., Costantino, J.P., Wickerham, D.L. et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388 (1998). Comprehensive set of data confirming that tamoxifen is a chemopreventive agent that can prevent about 50% of breast cancers in high risk patients, both pre and post menopausal.
10. Vogel, V.G., Costantino, J.P., Wickerham, D.L. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006).
11. Frasor, J., Danes, J.M., Komm, B., Chang, K.C., Lyttle, C.R., and Katzenellenbogen, B.S. Profiling of estrogen-up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562-4574 (2003).
12. Anzick, S.L., Kononen, J., Walker, R.L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997). Demonstration that over expression of coactivator proteins (here AIB1) can lead to abnormally high ER activity and pro-growth signals, presumably by simply changing the coactivator/corepressor ratio.
13. Lavinsky, R.M., Jepsen, K., Heinzel, T. et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. U.S.A. 95, 2920-2925 (1998). Corepressors are needed to maintain the inhibitory effects of tamoxifen on growth signaling. Again, the coactivator/corepressor ratio appears to be a key determinant.
14. Dickson, R.B. and Lippman, M.E. Growth factors in breast cancer. Endocr. Rev. 16, 559-589 (1995).
15. Paik, S., Hartmann, D.P., Dickson, R.B., and Lippman, M.E. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res. Treat. 31:301-307 (1994).
16. Osborne, C.K., Shou, J., Massarweh, S., and Schiff, R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. 11, 865s-870s (2005).
17. Morris, S.R. and Carey, L.A. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer. Oncology 20, 1763-1771 (2006).
18. Morris, C. and Wakeling, A. 2002. Fulvestrant (Faslodex) - a new treatment option for patients progressing on prior endocrine therapy. Endocr. Relat. Cancer 9, 267-276 (2002).
19. Dauvois, S., White, R., and Parker, M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106, 1377-1388 (1993). This paper follows on from one the previous year where the related compound, ICI 164,384 was shown to lead to degradation of ER, just as does ICI 182,780 (fulvestrant). These are referred to as "pure" antiestrogens.
20. Ariazi, E.A., Lewis-Wambi, J.S., Gill, S.D. et al. Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. J. Steroid Biochem. Mol. Biol. 102, 128-138 (2006).
21. Wang, L.H., Yang, X.Y., Zhang, X. et al. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10, 487-499 (2006). Targeting the DBD within ER will probably further potentiate SERM drugs that target the LBD, in the attempt to inhibit ER growth signaling.
22. Wang, L.H., Yang, X.Y., Zhang, X. et al. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat. Med. 10, 40-47 (2004).
23. Turpin, J.A., Terpening, S.J., Schaeffer, C.A., Yu, G., Glover, C.J., Felsted, R.L., Sausville, E.A., and Rice, W.G. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J. Virol. 70, 6180-6189 (1996).
24. Buzdar, A., Howell, A., Cuzick, J., Wale, C., Distler, W., Hoctin-Boes, G., Houghton, J., Locker, G.Y., and Nabholtz, J.M. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol. 7, 633-643 (2006).
25. Buzdar, A., Chlebowski, R., Cuzick, J., Duffy, S., Forbes, J., Jonat, W., and Ravdin, P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr. Med. Res. Opin. 22, 1575-1585 (2006).
26. Howell, A., Cuzick, J., Baum, M. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
27. Robertson, J.F., Osborne, C.K., Howell, A. et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 98, 229-238 (2003).
28. Jordan, V.C. and Brodie, A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72, 7-25 (2007). A nice historical view of the development of SERMs and AIs.
29. Winer, E.P., Hudis, C., Burstein, H.J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
30. Goldhirsch, A., Coates, A.S., Gelber, R.D., Glick, J.H., Thurlimann, B., Senn, H.J.; St Gallen Expert Panel Members. First - select the target: Better choice of adjuvant treatments for breast cancer patients. Ann. Oncol. 17, 1772-1776 (2006).
31. Rieber, A.G. and Theriault, R.L. Aromatase inhibitors in postmenopausal breast cancer patients. J. Natl. Compr. Canc. Netw. 3, 309-314 (2005).